Skip to content
DataLookout
Menu

FOCUSNCT07906080

Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study title shortened, about 4 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Feasibility of CIK (CIK_D332) cell therapy added to tafasitamab/lenalidomide in patients with relapsed/refractory DLBCL after at least one line of immuno-chemotherapy.
Timeframe: Through study completion, an average of 3 years
Safety of CIK (CIK_D332) cell therapy added to tafasitamab/lenalidomide in patients with relapsed/refractory DLBCL after at least one line of immuno-chemotherapy.
Timeframe: Through study completion, an average of 3 years

Secondary (4)

Feasibility of performing therapy on an outpatient basis
Overall Response Rate (ORR) according to 2007 International Working Group response criteria for malignant lymphoma at the End of Treatment
Complete Response Rate (CRR) according to 2007 International Working Group response criteria for malignant lymphoma at End of Treatment
Progression Free survival (PFS) according to 2007 International Working Group response criteria for malignant lymphoma at End of Treatment

Arms and interventions

ExperimentalExperimental

Cytokine Induced Killer-cells (CIK\_D332) in combination with Tafasitamab and Lenalidomide

Drugs: The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332

Sites

2 sites in 1 country